The B2B sector:using social media effectively to enhance business development

Research Question: 1. In which ways can social media in a B2B context be utilized to identify prospective customers, business partners or other stakeholders; to strengthen relationships; to create long-term value; to enter new markets or to develop products? 2. How can B2B companies achieve full potential of their social media activity? 3. Is it possible and recommendable for B2B companies to take a ‘B2C approach’ on social media in order to leverage business development? Research Purpose: The purpose of this research is to develop a deeper understanding of the social media phenomenon in a B2B context in relation to business development. Method: This research qualitatively analyzed contrasting case examples. The empirical data was collected through semi-structured interviews and assessed with the help of the thematic framework method. The theoretical chapter was built through an iterative approach. Conclusion: The empirical data of this analysis strongly indicate that social media can be used to enhance business development in the B2B context. Social media provides opportunities for B2B organizations to identify leads, to increase brand awareness, to sustain and develop relationships, to enter new markets and to innovate products and business processes

Disputatio Ethica, De Principiis Humanarum Actionum, Ex Tertio Arist. Ethic. lib. desumta

Ad cuius theses ... In illustri Iulia, sub praesidio M. Alberti Westphali Peinensis, Publice respondebit Henricus Iulius Riemschneider Grüningensis. Habebitur disputatio ... 11. Calend. Septembr. ..

Pathogenic classification of <i>LPL </i>gene variants reported to be associated with LPL deficiency

Lipoprotein lipase (LPL) deficiency is a serious lipid disorder of severe hypertriglyceridemia (SHTG) with chylomicronemia. A large number of variants in the LPL gene have been reported but their influence on LPL activity and SHTG has not been completely analyzed. Gaining insight into the deleterious effect of the mutations is clinically essential. We used gene sequencing followed by in-vivo/in-vitro and in-silico tools for classification. We classified 125 rare LPL mutations in 33 subjects thought to have LPL deficiency and in 314 subjects selected for very SHTG. Of the 33 patients thought to have LPL deficiency, only 13 were homozygous or compound heterozygous for deleterious mutations in the LPL gene. Among the 314 very SHTG patients, 3 were compound heterozygous for pathogenic mutants. In a third group of 51,467 subjects, from a general population, carriers of common variants, Asp9Asn and Asn291Ser, were associated with mild increase in triglyceride levels (11%-35%). In total, 39% of patients clinically diagnosed as LPL deficient had 2 deleterious variants. Three patients selected for very SHTG had LPL deficiency. The deleterious mutations associated with LPL deficiency will assist in the diagnosis and selection of patients as candidates for the presently approved LPL gene therap